Curis Inc (CRIS): Depreciation & Amortization
$169.0K
Year ended 2025-12-31
$84.0K
Trailing 12 months to 2026-06-30
-10.2%
3-year compound annual growth
+3.3%
5-year compound annual growth
+0.5%
10-year compound annual growth
| Period ended | Depreciation & Amortization | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $169.0K | -16.7% | 2026-03-24, From 2025-01-01 |
| 2024-12-31 | $203.0K | -20.4% | 2026-03-24, From 2024-01-01 |
| 2023-12-31 | $255.0K | +9.4% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $233.0K | +47.5% | 2024-02-08, From 2022-01-01 |
| 2021-12-31 | $158.0K | +9.7% | 2023-03-13, From 2021-01-01 |
| 2020-12-31 | $144.0K | +15.2% | 2022-02-24, From 2020-01-01 |
| 2019-12-31 | $125.0K | -29.4% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $177.0K | -24.7% | 2020-03-19, From 2018-01-01 |
| 2017-12-31 | $235.0K | +21.8% | 2019-03-26, From 2017-01-01 |
| 2016-12-31 | $193.0K | +19.9% | 2018-03-08, From 2016-01-01 |
| 2015-12-31 | $161.0K | +3.9% | 2018-03-08, From 2015-01-01 |
| 2014-12-31 | $155.0K | +9.5% | 2017-03-09, From 2014-01-01 |
| 2013-12-31 | $141.5K | +11.8% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $126.5K | +17.8% | 2015-02-24, From 2012-01-01 |
| 2011-12-31 | $107.4K | -84.4% | 2014-03-13, From 2011-01-01 |
| 2010-12-31 | $686.5K | -8.6% | 2013-03-13, From 2010-01-01 |
| 2009-12-31 | $751.2K | n/a | 2012-02-29, From 2009-01-01 |
Depreciation & Amortization at similar companies
| Company | Year ended | Depreciation & Amortization | Change YoY |
|---|---|---|---|
| Curis Inc (CRIS) | 2025-12-31 | $169.0K | -16.7% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $58.6K | -27.9% |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | $2.90M | -29.3% |
| Caribou Biosciences, Inc. (CRBU) | 2025-12-31 | $3.65M | -7.2% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $12.90M | -32.0% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $699.0K | +19.1% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $2.99M | +9.8% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $73.0K | -1.4% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $287.0K | +394.8% |
Compare CRIS, ACOG, TCRX, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗